Storia in 5 fonti

A turning point for pancreatic cancer patients

Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout

Raccontata da

pharmaceutical-technology.com

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

fiercepharma.com3 mesi fa

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | Although the first-in-class PD-1xVEGF bispecific didn’t disappoint on its overall survival…

Leggi questa versione → originale

Timeline cronologica

sabato 30 maggio 2026·statnews.com
BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA
ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.
sabato 30 maggio 2026·statnews.com
BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA
ASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.

A turning point for pancreatic cancer patients

Confronto fonti

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

Timeline cronologica

BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA

BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

ASCO in brief: Lilly's plenaries; Incyte's frontline data in lymphoma

ASCO: Revolution Medicines confident in RAS leadership as rivals square up

ASCO26: In vivo oncology approaches continue to show promise

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer

ASCO: Revolution Medicines confident in RAS leadership as rivals square up

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

A standing ovation for RevMed, and caution for Akeso

A turning point for pancreatic cancer patients

Pharmalittle: We're reading about pancreatic and lung cancer drugs, China biotech growth, and more

ASCO in brief: Lilly's plenaries; Incyte's frontline data in lymphoma

ASCO26: In vivo oncology approaches continue to show promise

As Akeso takes center stage at ASCO, China biotech industry cements its coming of age

Legend Biotech emerged as a rare market winner